Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Technology

This article was originally published in The Gray Sheet

Executive Summary

Announces FDA approval to begin 425-patient, seven-site clinical study examining use of its excimer laser system for laser-assisted automated lamellar keratectomy (ALK) treatment of nearsightedness of up to 25 diopters. In the outpatient procedure, a "flap" of tissue is removed from the cornea. The excimer laser is used to make a refractive correction directly on the cornea or on the flap, which is then replaced in the eye. Summit has a premarket approval application pending for use of the excimer laser to treat nearsightedness of up to five diopters via photorefractive keratectomy
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT038092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel